Defining the optimal sequence for the systemic treatment of metastatic breast cancer


Por: Mestres JA, iMolins AB, Martínez LC, López-Muñiz JI, Gil EC, de Juan Ferré A, Del Barco Berrón S, Pérez YF, Mata JG, Palomo AG, Gregori JG, Pardo PG, Mañas JJ, Hernández AL, de Dueñas EM, Jáñez NM, Murillo SM, Bofill JS, Auñón PZ, Sanchez-Rovira P

Publicada: 1 feb 2017
Resumen:
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered in the previous stages, such as acquired resistance, type of progression, time to relapse, tumor aggressiveness, age, comorbidities, pre- and post-menopausal status, and patient preferences. Moreover, tumor genomic signatures can identify different subtypes, which can be used to create patient profiles and design specific therapies. However, there is no consensus regarding the best treatment sequence for each subgroup of patients. During the SABCC Congress of 2014, specialized breast cancer oncologists from referral hospitals in Europe met to define patient profiles and to determine specific treatment sequences for each one. Conclusions were then debated in a final meeting in which a relative degree of consensus for each treatment sequence was established. Four patient profiles were defined according to established breast cancer phenotypes: pre-menopausal patients with luminal subtype, post-menopausal patients with luminal subtype, patients with triple-negative subtype, and patients with HER2-positive subtype. A treatment sequence was then defined, consisting of hormonal therapy with tamoxifen, aromatase inhibitors, fulvestrant, and mTOR inhibitors for pre- and post-menopausal patien ts; a chemotherapy sequence for the first, second, and further lines for luminal and triple-negative patients; and an optimal sequence for treatment with new antiHER2 therapies. Finally, a document detailing all treatment sequences, that had the agreement of all the oncologists, was drawn up as a guideline and advocacy tool for professionals treating patients with this disease.

Filiaciones:
Mestres JA:
 Hospital del Mar, Barcelona, Spain

iMolins AB:
 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Martínez LC:
 Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

López-Muñiz JI:
 Hospital Virgen de la Salud, Toledo, Spain

Gil EC:
 Hospital Universitario 12 de Octubre, Madrid, Spain

de Juan Ferré A:
 Hospital Universitario Marqués de Valdecilla, Santander, Spain

Del Barco Berrón S:
 Institut Català d'Oncologia, Girona, Spain

Pérez YF:
 Hospital Universitario Central de Asturias, Oviedo, Spain

Mata JG:
 Hospital Santa María Nai en Ourense, Orense, Spain

Palomo AG:
 Complejo Asistencial de León, Léon, Spain

Gregori JG:
 Fundación Instituto Valenciano de Oncología, Valencia, Spain

Pardo PG:
 Hospital Universitari Vall d'Hebron, Barcelona, Spain

Mañas JJ:
 Complejo Hospitalario de Navarra, Pamplona, Spain

Hernández AL:
 Hospital Clínic Universitari de València, València, Spain

de Dueñas EM:
 Consorcio Hospitalario i Provincial de Castellón, Castellón, Spain

Jáñez NM:
 Hospital Universitario Ramón y Cajal, Madrid, Spain

Murillo SM:
 Hospital Universitari Arnau de Vilanova, Lleida, Spain

Bofill JS:
 Hospital Universitario Nuestra Señora de Valme, Seville, Spain

Auñón PZ:
 Hospital Universitario La Paz, Madrid, Spain

Sanchez-Rovira P:
 Complejo Hospitalario de Jaén, Jaén, Spain.
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 19 Número: 2
Páginas: 149-161
WOS Id: 000392315900002
ID de PubMed: 27314861

MÉTRICAS